Analys

Camurus (Q3 Review): Buvidal Slow, but GLP-1 Shows Promise - Redeye

{newsItem.title}

Redeye Publicerad: 11 Nov 10:45

Redeye comments on Camurus' Q3 report 2025, which was below our estimates due to a sequential sales decline of Buvidal sales in Europe. After the third quarter report, Camurus reported a strong phase I readout of CAM2056, the company's GLP-1 candidate.

Länk till analysen i sin helhet: https://www.redeye.se/research/1137824/camurus-q3-review-buvidal-slow-but-glp-1-shows-promise?utm_source=finwire&utm_medium=RSS

Nyheter om Camurus

Läses av andra just nu

Om aktien Camurus

Senaste nytt